Combined entity will offer solutions to pharma, biopharma, and diagnostic firms.
Eurogentec negotiated a final agreement for the acquisition of Fremont, CA-based AnaSpec. The company is a specialist provider of integrated proteomics solutions for life science research and diagnostics.
Eurogentec claims combining AnaSpec’s expertise with its own capabilities will allow it to provide innovative solutions in the fields of genomics and proteomics for basic research in the biotech and pharma sectors as well as applied solutions for the diagnostics industry. For example, comments Jean-Pierre Delward, Eurogentec CEO, “The HiLyte Fluor™ dyes and QXL™ quenchers that are part of AnaSpec’s high-performance detection assays will be integrated into Eurogentec’s comprehensive portfolio of oligonucleotides. This will establish a license-friendly alternative to most dye-labeled oligonucleotides from competitors for commercial and diagnostic applications.”
Eurogentec also points out that the AnaSpec acquisition will significantly strengthen its presence in the U.S. The company plans to market and support AnaSpec’s products directly in the EU.
AnaSpec’s current product and service portfolio includes GMP and GLP custom peptide synthesis labeled primary antibodies, labeled secondary antibodies, and labeled streptavidin. The company also claims to offer one of the largest collections of catalog and dye-labeled peptides in the fields of Alzheimer’s disease, multiple sclerosis, and enzyme inhibitor screening. AnaSpec moved into its new, 44,010 square foot headquarters in Fremont in April.